Literature DB >> 33488626

LAG3's Enigmatic Mechanism of Action.

Colin G Graydon1, Shifa Mohideen1, Keith R Fowke1,2,3,4.   

Abstract

LAG3 is an important immune checkpoint with relevance in cancer, infectious disease and autoimmunity. However, despite LAG3's role in immune exhaustion and the great potential of LAG3 inhibition as treatment, much remains unknown about its biology, particularly its mechanism of action. This review describes the knowns, unknowns and controversies surrounding LAG3. This includes examination of how LAG3 is regulated transcriptionally and post-translationally by endocytosis and proteolytic cleavage. We also discuss the interactions of LAG3 with its ligands and the purpose thereof. Finally, we review LAG3's mechanism of action, including the roles of LAG3 intracellular motifs and the lack of a role for CD4 competition. Overall, understanding the biology of LAG3 can provide greater insight on LAG3 function, which may broaden the appreciation for LAG3's role in disease and potentially aid in the development of targeted therapies.
Copyright © 2021 Graydon, Mohideen and Fowke.

Entities:  

Keywords:  LAG3; Lymphocyte activation gene-3; checkpoint inhibition; immune checkpoint; immune checkpoint inhibitors; immune exhaustion; mechanism of action

Mesh:

Substances:

Year:  2021        PMID: 33488626      PMCID: PMC7820757          DOI: 10.3389/fimmu.2020.615317

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  55 in total

1.  Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells.

Authors:  F Annunziato; R Manetti; L Cosmi; G Galli; C H Heusser; S Romagnani; E Maggi
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

2.  LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses.

Authors:  Feng Xu; Jing Liu; Di Liu; Biao Liu; Min Wang; Zhiyuan Hu; Xuemei Du; Li Tang; Fuchu He
Journal:  Cancer Res       Date:  2014-04-25       Impact factor: 12.701

3.  Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity.

Authors:  Christopher E Rudd; Kittiphat Chanthong; Alison Taylor
Journal:  Cell Rep       Date:  2020-02-18       Impact factor: 9.423

4.  Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.

Authors:  Takeo K Maeda; Daisuke Sugiura; Il-Mi Okazaki; Takumi Maruhashi; Taku Okazaki
Journal:  J Biol Chem       Date:  2019-02-13       Impact factor: 5.157

5.  Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (gene-capture PCR).

Authors:  R Mastrangeli; E Micangeli; S Donini
Journal:  Anal Biochem       Date:  1996-10-01       Impact factor: 3.365

6.  Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.

Authors:  Anne Fröhlich; Judith Sirokay; Simon Fietz; Timo J Vogt; Jörn Dietrich; Romina Zarbl; Mike Florin; Pia Kuster; Gonzalo Saavedra; Susana Ramírez Valladolid; Friederike Hoffmann; Lukas Flatz; Sandra S Ring; Carsten Golletz; Torsten Pietsch; Sebastian Strieth; Peter Brossart; Gerrit H Gielen; Glen Kristiansen; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  EBioMedicine       Date:  2020-08-30       Impact factor: 8.143

7.  Egr-2 transcription factor is required for Blimp-1-mediated IL-10 production in IL-27-stimulated CD4+ T cells.

Authors:  Yukiko Iwasaki; Keishi Fujio; Tomohisa Okamura; Atsushi Yanai; Shuji Sumitomo; Hirofumi Shoda; Tomohiko Tamura; Hiroki Yoshida; Patrick Charnay; Kazuhiko Yamamoto
Journal:  Eur J Immunol       Date:  2013-02-26       Impact factor: 5.532

8.  A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases.

Authors:  Mathieu Angin; Chrystelle Brignone; Frédéric Triebel
Journal:  J Immunol       Date:  2020-01-06       Impact factor: 5.422

9.  CPAP is a novel stat5-interacting cofactor that augments stat5-mediated transcriptional activity.

Authors:  Benjamin Peng; Kate D Sutherland; Eleanor Y M Sum; Monilola Olayioye; Sergio Wittlin; Tang K Tang; Geoffrey J Lindeman; Jane E Visvader
Journal:  Mol Endocrinol       Date:  2002-09

10.  TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion.

Authors:  Omar Khan; Josephine R Giles; Sierra McDonald; Sasikanth Manne; Shin Foong Ngiow; Kunal P Patel; Michael T Werner; Alexander C Huang; Katherine A Alexander; Jennifer E Wu; John Attanasio; Patrick Yan; Sangeeth M George; Bertram Bengsch; Ryan P Staupe; Greg Donahue; Wei Xu; Ravi K Amaravadi; Xiaowei Xu; Giorgos C Karakousis; Tara C Mitchell; Lynn M Schuchter; Jonathan Kaye; Shelley L Berger; E John Wherry
Journal:  Nature       Date:  2019-06-17       Impact factor: 49.962

View more
  28 in total

1.  Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effects of electroconvulsive stimulation.

Authors:  Neta Rimmerman; Hodaya Verdiger; Hagar Goldenberg; Lior Naggan; Elad Robinson; Ewa Kozela; Sivan Gelb; Ronen Reshef; Karen M Ryan; Lily Ayoun; Ron Refaeli; Einat Ashkenazi; Nofar Schottlender; Laura Ben Hemo-Cohen; Claudia Pienica; Maayan Aharonian; Eyal Dinur; Koby Lazar; Declan M McLoughlin; Ayal Ben Zvi; Raz Yirmiya
Journal:  Mol Psychiatry       Date:  2021-10-14       Impact factor: 15.992

2.  LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.

Authors:  Qianqian Ming; Daiana P Celias; Chao Wu; Aidan R Cole; Srishti Singh; Charlotte Mason; Shen Dong; Timothy H Tran; Gaya K Amarasinghe; Brian Ruffell; Vincent C Luca
Journal:  Nat Immunol       Date:  2022-06-27       Impact factor: 31.250

3.  Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.

Authors:  Han Zhu; Francisco X Galdos; Daniel Lee; Sarah Waliany; Yuhsin Vivian Huang; Julia Ryan; Katherine Dang; Joel W Neal; Heather A Wakelee; Sunil A Reddy; Sandy Srinivas; Lih-Ling Lin; Ronald M Witteles; Holden T Maecker; Mark M Davis; Patricia K Nguyen; Sean M Wu
Journal:  Circulation       Date:  2022-06-28       Impact factor: 39.918

4.  Overcoming the LAG3 phase problem.

Authors:  Jan Petersen; Jamie Rossjohn
Journal:  Nat Immunol       Date:  2022-07       Impact factor: 31.250

Review 5.  Immune checkpoint inhibitors for the treatment of melanoma.

Authors:  Francesco Sabbatino; Luigi Liguori; Stefano Pepe; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2022-02-13       Impact factor: 5.589

Review 6.  Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases.

Authors:  Sai Harsha Krovi; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2022-02-10       Impact factor: 10.983

7.  LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.

Authors:  Eunsil Sung; Minkyung Ko; Ju-Young Won; Yunju Jo; Eunyoung Park; Hyunjoo Kim; Eunji Choi; Ui-Jung Jung; Jaehyoung Jeon; Youngkwang Kim; Hyejin Ahn; Da-Som Choi; Seunghyun Choi; Youngeun Hong; Hyeyoung Park; Hanbyul Lee; Yong-Gyu Son; Kyeongsu Park; Jonghwa Won; Soo Jin Oh; Seonmin Lee; Kyu-Pyo Kim; Changhoon Yoo; Hyun Kyu Song; Hyung-Seung Jin; Jaeho Jung; Yoon Park
Journal:  Mol Ther       Date:  2022-05-06       Impact factor: 12.910

8.  LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.

Authors:  Christian Sordo-Bahamonde; Seila Lorenzo-Herrero; Ana P González-Rodríguez; Ángel R Payer; Esther González-García; Alejandro López-Soto; Segundo Gonzalez
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

9.  In Situ Overexpression of Matricellular Mechanical Proteins Demands Functional Immune Signature and Mitigates Non-Small Cell Lung Cancer Progression.

Authors:  Lygia Bertalha Yaegashi; Camila Machado Baldavira; Tabatha Gutierrez Prieto; Juliana Machado-Rugolo; Ana Paula Pereira Velosa; Lizandre Keren Ramos da Silveira; Aline Assato; Alexandre Muxfeldt Ab'Saber; Roberto Falzoni; Teresa Takagaki; Pedro Leme Silva; Walcy Rosolia Teodoro; Vera Luiza Capelozzi
Journal:  Front Immunol       Date:  2021-08-16       Impact factor: 7.561

Review 10.  Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise.

Authors:  Brian Healey Bird; Ken Nally; Karine Ronan; Gerard Clarke; Sylvie Amu; Ana S Almeida; Richard Flavin; Stephen Finn
Journal:  Diagnostics (Basel)       Date:  2022-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.